Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REALTA

Financiado

Challenging Hypertension Through Novel Medical Device Development

Hypertension directly causes approximately 25% of heart attacks in Europe and, in its progressed form of cardiovascular disease, it is estimated to cause 42% of all deaths across Europe annually. Untreated hypertension is one of t... ver más

31/12/2018

OLLSCOIL NA GAILLI...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

2 Participantes

OLLSCOIL NA GAILLIMHE

149.95K€ | Lider

PRECICAST BILBAO, S.A.

626.10K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BES-2012-051904 NUEVOS VASODILATADORES PARA LA HIPERTENSION PULMONAR 43K€ Cerrado

PID2021-123167OB-I00 NUEVAS DIANAS Y ESTRATEGIAS TERPAEUTICAS EN LA HIPERTENSION... 200K€ Cerrado

PAH-Advance PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a dise... 4M€ Cerrado

EIN2019-103130 ESTUDIO MULTIDISCIPLINAR INTEGRADO DE LA FISIOPATOLOGIA Y EL... 22K€ Cerrado

PTQ-11-04860 NUEVOS COMPUESTOS PARA EL TRATAMIENTO DE LA ENFERMEDAD CARDI... 104K€ Cerrado

JCI-2011-09598 HIPERTENSIÓN ARTERIAL Y RIESGO CARDIOVASCULAR: EVOLUCIÓN DEL... 96K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2017-06-09
Fecha Fin: 2018-12-31

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Hypertension directly causes approximately 25% of heart attacks in Europe and, in its progressed form of cardiovascular disease, it is estimated to cause 42% of all deaths across Europe annually. Untreated hypertension is one of the primary contributors to a number of the medical conditions with the greatest burden of care, including stroke, dementia and kidney failure. One of the most promising avenues for the treatment of hypertension has been research into primary aldosteronism (PA). In the last ten years, PA has been recognised as the most common curable cause of hypertension. PA is thought to account for up to 18% of all cases of hypertension within the population and is caused by benign shallow adenomas on the surface of the adrenal gland. Researchers have identified the effective treatment of PA as a clear mechanism to address Europe’s hypertension problem. However, finding an effective surgical or pharmaceutical treatment for PA has been challenging to date. Radiofrequency ablation (RFA) has also been evaluated for the treatment of adrenal cancer . RFA involves the insertion of an ablation needle into adrenal adenoma and passing high frequency electrical current into the gland. The weakness of RFA is that it produces a large ablation zone, which is particular problematic in a small organ typically less than 5cm3 in volume. In many cases, a large proportion of the functional cortex tissue surrounding the adenoma can be destroyed during the RFA process , thereby negating the benefit of the RFA over the traditional adrenalectomy approach. An ideal ablation technology would involve a custom-designed microwave ablation device capable of destroying the shallow adrenal adenoma, while simultaneously protecting the delicate tissue of the remaining gland. That is precisely what is proposed in the REALTA project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores